Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.
Unicycive Therapeutics Trading Down 2.0 %
NASDAQ:UNCY opened at $0.61 on Monday. The stock has a 50-day moving average price of $0.59 and a 200 day moving average price of $0.57. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.60. The stock has a market capitalization of $63.73 million, a P/E ratio of -0.63 and a beta of 2.26.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Unicycive Therapeutics in a research report on Wednesday, January 29th.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Netflix Poised for Significant Rally as a Safe Haven Stock
- What is diluted earnings per share (Diluted EPS)?
- Lululemon Pulls Back Into Classic Dip-Buying Opportunity
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Cintas Delivers Earnings Beat, Signals More Growth Ahead
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
